Search results
Advancements in Triglyceride-lowering Therapies
Video Series
Added:
6 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by BETTER-BP Principal Investigator Dr John Dodson (NYU Langone Health, New York, US) to present the findings of this AHA late-breaking trial (NCT04114669).The BETTER-BP (Behavioral Economics Trial to Enhance Regulation of Blood Pressure) is a phase II pragmatic randomized…
View more
Lipid-lowering Therapies and Lp(a)
Added:
1 month ago
Review Article
Added:
1 month ago
Added:
1 month ago
Source:
Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England…
View more
Added:
1 month ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc analysis of the SURPASS-CVOT trial suggests that tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a lower incidence of a broad composite of cardiorenal events compared with the GLP-1 receptor agonist dulaglutide in patients with type 2 diabetes and established cardiovascular disease.¹Tirzepatide is a dual agonist that targets both…
View more
Added:
1 year ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive…
View more
Added:
1 month ago
Added:
7 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
For patients with heterozygous familial hypercholesterolemia (HeFH), achieving adequate low-density lipoprotein cholesterol (LDL-C) lowering remains a significant challenge. New results from the BROOKLYN trial suggest that the investigational agent obicetrapib could be an effective add-on therapy for this high-risk population.¹Mechanism of ActionObicetrapib is a highly selective cholesteryl ester…
View more